Evidence Hub

Antibiotic resistance mutations in Mycoplasma genitalium and non-gonococcal urethritis treatment outcomes

Adriaens N, Bruisten SM, Westerhuis BM, van Dam AP, Schim van der Loeff MF, Doelman TA, Noordpool L, de Vries HJC et al.

Sexually transmitted diseases, 2026

14 participants

Abstract

Background: In the Netherlands, Mycoplasma genitalium (MG) shows high macrolide resistance (75%) and increasing fluoroquinolone resistance (10%), limiting azithromycin and moxifloxacin efficacy. Despite high macrolide resistance, non-gonococcal urethritis (NGU) guidelines recommend delaying moxifloxacin until four weeks after azithromycin. This study evaluated microbiological and clinical cure of MG following sequential azithromycin and moxifloxacin treatment in relation to antibiotic resistance.

Methods: Men with NGU at the Centre for Sexual Health Amsterdam underwent physical examination and urine testing. MG-positive participants were followed up to 6 weeks. All received azithromycin 1 g at baseline; moxifloxacin was administered at week 4 for persistent MG-NGU. Macrolide (23S rRNA, rplD, rplV) and fluoroquinolone (parC, parE, gyrA, gyrB) resistance mutations and mgpB genotypes were assessed using nanopore sequencing.

Results: Among 30 MG-NGU cases, azithromycin achieved low microbiological cure, with 22 remaining positive at week 4. By week 6, 21 participants attended follow-up. Moxifloxacin was prescribed to 14 participants: 1 with persistent NGU and MG positivity, 5 with persistent NGU despite MG clearance, 3 with persistent MG without NGU, and 5 with resolution of both. Among the 7 untreated participants, 5 remained MG-positive with persistent NGU and 2 remained MG-positive without NGU. Symptoms generally improved despite persistent microbiological or clinical…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free